5w0l

CREBBP Bromodomain in complex with Cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)

Method: X-RAY DIFFRACTION D_max: 85.6 Å Quality: GOOD

▼

1. 蛋白身份与相关结构 Protein Identity & Related Structures

CREB-binding protein

Homo sapiens

当前结构中的状态

Assembly	聚集状态	构建体	突变与修饰	配体、离子与共同组分	实验方法与环境	结构质量
1	蛋白单体单体蛋白 × 1 PDB 声明：monomeric（1）与蛋白拷贝数一致	链 A； UniProt 1082–1197	片段：Bromodomain, UNP residues 1082-1197	9UD 1-{3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件：VAPOR DIFFUSION；pH 6.5；277 K；100 mM Bis-Tris pH 5.5, 200-300 mM KSCN, 21-25% PEG 3350	分辨率 1.55 Å R-free 0.229
2	蛋白单体单体蛋白 × 1 PDB 声明：monomeric（1）与蛋白拷贝数一致	链 B； UniProt 1082–1197	片段：Bromodomain, UNP residues 1082-1197	9UD 1-{3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件：VAPOR DIFFUSION；pH 6.5；277 K；100 mM Bis-Tris pH 5.5, 200-300 mM KSCN, 21-25% PEG 3350	分辨率 1.55 Å R-free 0.229

数据库中的同蛋白其他状态

以下每一行都是同一 UniProt 蛋白在另一个 PDB 条目中的 biological assembly， “相对当前条目”直接指出证据层面的不同；没有差异标签表示当前已读取字段一致。

其他 PDB	相对当前条目 5W0L	Assembly / 聚集状态	构建体	突变与修饰	配体、离子与非聚合物	实验方法与环境	结构质量
1JSP NMR Structure of CBP Bromodomain in complex with p53 peptide 提交 2001-08-17	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 B 1081–1197（117 aa）片段：bromodomain	未记录	未记录非水小分子	SOLUTION NMR NMR测量条件 pH 6.5；298 K；压力 ambient NMR测量条件 pH 6.5；298 K；压力 ambient NMR测量条件 pH 6.5；298 K；压力 ambient NMR测量条件 pH 6.5；298 K；压力 ambient NMR样品组成 0.5mM CBP bromodomain U-15N; 0.5mM P53 peptide; 100mM phosphate buffer; pH 6.5 \| 90% H2O/10% D2O NMR样品组成 0.5mM CBP bromodomain U-15N,13C; 0.5mM P53 peptide;100mM phosphate buffer; pH 6.5 \| 90% H2O/10% D2O NMR样品组成 0.5mM CBP bromodomain U-15N,13C; 0.5mM P53 peptide;100mM phosphate buffer; pH 6.5 \| 99.9%D2O NMR样品组成 0.5mM CBP bromodomain U-15N,13C,75% 2H; 0.5mM P53 peptide;100mM phosphate buffer; pH 6.5 \| 90% H2O/10% D2O	分辨率未提供
1LIQ Non-native Solution Structure of a fragment of the CH1 domain of CBP 提交 2002-04-18	构建体不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 376–402（27 aa）片段：RESIDUES 1-27	未记录	ZN ZINC ION × 1	SOLUTION NMR NMR测量条件 pH 6.5；275 K；压力 ambient NMR样品组成 0.4mM CBP(376-402), 0.6mM TCEP, 0.6mM ZnSO4, 95% H2O, 10% D2O \| 95% H2O, 10% D2O NMR样品组成 0.4mM CBP(376-402), 0.6mM TCEP, 0.6mM ZnSO4, 100% D2O \| 100% D2O	分辨率未提供
1WO3 Solution structure of Minimal Mutant 1 (MM1): Multiple alanine mutant of non-native CHANCE domain 提交 2004-08-12	构建体不同突变/修饰不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 376–400（25 aa）片段：CBP	突变：E1A, R3S, S6A, H9K, R11A, T12A, M13A, K14A, L17A, N18A, Q24A, A25K	ZN ZINC ION × 1	SOLUTION NMR NMR测量条件 pH 6.9；275 K；离子强度（mmCIF原始值）0；压力 ambient NMR样品组成 0.4mM MM1, 0.5mM TCEP, 1mM ZnSO4, 5% D2O \| 95% H2O/5% D2O NMR样品组成 0.4mM MM1, 0.5mM TCEP, 1mM ZnSO4, 100% D2O \| 100% D2O	分辨率未提供
1WO4 Solution structure of Minimal Mutant 2 (MM2): Multiple alanine mutant of non-native CHANCE domain 提交 2004-08-12	构建体不同突变/修饰不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 376–400（25 aa）片段：CBP	突变：E1A, R3S, S6A, P8S, H9K, R11A, T12A, M13A, K14A, L17A, N18A, Q24A, A25K	ZN ZINC ION × 1	SOLUTION NMR NMR测量条件 pH 6.9；275 K；离子强度（mmCIF原始值）0；压力 ambient NMR样品组成 0.4mM MM2, 0.5mM TCEP, 1mM ZnSO4, 5% D2O \| 95% H2O/5% D2O NMR样品组成 0.4mM MM2, 0.5mM TCEP, 1mM ZnSO4, 100% D2O \| 100% D2O	分辨率未提供
1WO5 Solution structure of Designed Functional Finger 2 (DFF2): Designed mutant based on non-native CHANCE domain 提交 2004-08-12	构建体不同突变/修饰不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 376–400（25 aa）片段：CBP	突变：E1R, R3I, S6F, P8K, H9V, R11A, T12A, M13A, K14A, L17A, N18A, Q24A, A25K	ZN ZINC ION × 1	SOLUTION NMR NMR测量条件 pH 6.9；275 K；离子强度（mmCIF原始值）0；压力 ambient NMR样品组成 0.3mM DFF2, 0.5mM TCEP, 1mM ZnSO4, 5% D2O \| 95% H2O/5% D2O	分辨率未提供
1WO6 Solution structure of Designed Functional Finger 5 (DFF5): Designed mutant based on non-native CHANCE domain 提交 2004-08-12	构建体不同突变/修饰不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 376–400（25 aa）片段：CBP	突变：E1A, R3Y, A4Y, S6I, H9K, R11A, T12A, M13A, K14A, L17A, N18A, M20T, Q24F, A25K	ZN ZINC ION × 1	SOLUTION NMR NMR测量条件 pH 7.2；275 K；离子强度（mmCIF原始值）0；压力 ambient NMR样品组成 0.3mM DFF5, 0.5mM TCEP, 1mM ZnSO4, 5% D2O \| 95% H2O/5% D2O	分辨率未提供
1WO7 Solution structure of Designed Functional Finger 7 (DFF7): Designed mutant based on non-native CHANCE domain 提交 2004-08-12	构建体不同突变/修饰不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 376–400（25 aa）片段：CBP	突变：E1F, R3S, A4T, S6Y, H9K, R11A, T12A, M13A, K14A, L17A, N18A, M20I, Q24Y, A25K	ZN ZINC ION × 1	SOLUTION NMR NMR测量条件 pH 7；275 K；离子强度（mmCIF原始值）0；压力 ambient NMR样品组成 0.25mM DFF7, 0.5mM TCEP, 1mM ZnSO4, 5% D2O \| 95% H2O/5% D2O	分辨率未提供
1ZOQ IRF3-CBP complex 提交 2005-05-13	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 C 2065–2111（47 aa）	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.2 M ammonium acetate, 0.15 M Mg acetate, 5% (v/v) PEG 4000, 50 mM Na HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.37 Å R-free 0.226
1ZOQ IRF3-CBP complex 提交 2005-05-13	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 D 2065–2111（47 aa）	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.2 M ammonium acetate, 0.15 M Mg acetate, 5% (v/v) PEG 4000, 50 mM Na HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.37 Å R-free 0.226
2D82 Target Structure-Based Discovery of Small Molecules that Block Human p53 and CREB Binding Protein (CBP) Association 提交 2005-12-01	构建体不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：Bromodomain	未记录	TTR 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE × 1	SOLUTION NMR NMR测量条件 pH 6.5；298 K；压力 AMBIENT NMR样品组成 0.5MM CBP BROMODOMAIN U-15N, 13C; 3.0MM CRB Ligand; 100MM PHOSPHATE BUFFER; PH 6.5 \| 100% D2O NMR样品组成 0.5MM CBP BROMODOMAIN U-15N, 13C, 75% 2H; 3.0MM CRB Ligand; 100MM PHOSPHATE BUFFER; PH 6.5 \| 90% H2O/10% D2O	分辨率未提供
2KJE NMR structure of CBP TAZ2 and adenoviral E1A complex 提交 2009-05-27	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 1763–1854（92 aa）片段：UNP residues 1763-1854	未记录	ZN ZINC ION × 3	SOLUTION NMR NMR测量条件 pH 6.8；298 K；离子强度（mmCIF原始值）0；压力 ambient NMR样品组成 1-1.5 mM [U-100% 13C; U-100% 15N] TRIS-1, 1-1.5 mM [U-100% 15N] TRIS-2, 100% D2O \| 100% D2O	分辨率未提供
2KWF The structure of E-protein activation domain 1 bound to the KIX domain of CBP/p300 elucidates leukemia induction by E2A-PBX1 提交 2010-04-08	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 587–673（87 aa）片段：UNP residues 587-673, KIX domain	未记录	未记录非水小分子	SOLUTION NMR NMR测量条件 pH 6；298 K；离子强度（mmCIF原始值）0；压力 ambient NMR样品组成 1 mM DSS-1, 20 mM MES-2, 1 mM beta-mercaptoethanol-3, 90% H2O/10% D2O \| 90% H2O/10% D2O	分辨率未提供
2L84 Solution NMR structures of CBP bromodomain with small molecule j28 提交 2011-01-03	构建体不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：Bromo domain residues 1081-1197	未记录	J28 5-[(E)-(2-amino-4-hydroxy-5-methylphenyl)diazenyl]-2,4-dimethylbenzenesulfonic acid × 1	SOLUTION NMR NMR测量条件 pH 6.5；298 K；压力 ambient NMR样品组成 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM J28, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 90% H2O/10% D2O \| 90% H2O/10% D2O NMR样品组成 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM J28, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 100% D2O \| 100% D2O	分辨率未提供
2L85 Solution NMR structures of CBP bromodomain with small molecule of HBS 提交 2011-01-04	构建体不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：BROMO DOMAIN residues 1081-1197	未记录	L85 4-[(E)-(4-hydroxyphenyl)diazenyl]benzenesulfonic acid × 1	SOLUTION NMR NMR测量条件 pH 6.5；298 K；压力 ambient NMR样品组成 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM (E)-4-((4-hydroxyphenyl)diazenyl)benzenesulfonic acid, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 90% H2O/10% D2O \| 90% H2O/10% D2O NMR样品组成 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM (E)-4-((4-hydroxyphenyl)diazenyl)benzenesulfonic acid, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 100% D2O \| 100% D2O	分辨率未提供
2LXS Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic core 提交 2012-08-31	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 587–673（87 aa）片段：UNP RESIDUES 587-673	未记录	未记录非水小分子	SOLUTION NMR NMR测量条件 pH 5.8；300 K；压力 ambient NMR样品组成 1 mM [U-100% 13C; U-100% 15N] entity_1-1, 2 mM [U-100% 13C; U-100% 15N] entity_2-2, 25 mM sodium chloride-3, 50 mM potassium phosphate-4, 1 mM sodium azide-5, 90% H2O/10% D2O \| 90% H2O/10% D2O	分辨率未提供
2LXT Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic core 提交 2012-08-31	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 3 PDB 声明：trimeric	链 A 587–673（87 aa）片段：UNP RESIDUES 587-673	未记录	未记录非水小分子	SOLUTION NMR NMR测量条件 pH 5.8；300 K；压力 ambient NMR样品组成 1 mM [U-100% 13C; U-100% 15N] entity_1-1, 2 mM entity_2-2, 2 mM [U-100% 13C; U-100% 15N] entity_3-3, 25 mM sodium chloride-4, 50 mM potassium phosphate-5, 1 mM sodium azide-6, 90% H2O/10% D2O \| 90% H2O/10% D2O	分辨率未提供
2N1A Docked structure between SUMO1 and ZZ-domain from CBP 提交 2015-03-26	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 B 1699–1751（53 aa）	未记录	ZN ZINC ION × 2	SOLUTION NMR NMR测量条件 pH 6；298 K；压力 ambient NMR样品组成 20 mM MES, 93% H2O/7% D2O \| 93% H2O/7% D2O NMR样品组成 20 mM MES, 90% H2O, 10% D2O \| 90% H2O/10% D2O	分辨率未提供
2RNY Complex Structures of CBP Bromodomain with H4 ack20 Peptide 提交 2008-02-03	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	未记录非水小分子	SOLUTION NMR NMR测量条件 pH 6.5；298 K；离子强度（mmCIF原始值）0.1；压力 ambient NMR样品组成 0.5mM [U-100% 13C; U-100% 15N] sodium phosphate, 100% D2O \| 100% D2O	分辨率未提供
3DWY Crystal Structure of the Bromodomain of Human CREBBP 提交 2008-07-23	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：Bromo domain: residues 1084-1197	未记录	EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN, 25% PEG3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.98 Å R-free 0.219
3DWY Crystal Structure of the Bromodomain of Human CREBBP 提交 2008-07-23	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：Bromo domain: residues 1084-1197	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN, 25% PEG3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.98 Å R-free 0.219
3P1C Crystal structure of the bromodomain of human CREBBP in complex with acetylated lysine 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	ALY N(6)-ACETYLLYSINE × 1 SCN THIOCYANATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.82 Å R-free 0.218
3P1C Crystal structure of the bromodomain of human CREBBP in complex with acetylated lysine 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	ALY N(6)-ACETYLLYSINE × 1 K POTASSIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.82 Å R-free 0.218
3P1D Crystal structure of the bromodomain of human CREBBP in complex with N-Methyl-2-pyrrolidone (NMP) 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：Bromo domain, UNP residues 1081-1197	未记录	SCN THIOCYANATE ION × 1 MB3 1-methylpyrrolidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 20% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.86 Å R-free 0.218
3P1D Crystal structure of the bromodomain of human CREBBP in complex with N-Methyl-2-pyrrolidone (NMP) 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：Bromo domain, UNP residues 1081-1197	未记录	MB3 1-methylpyrrolidin-2-one × 1 K POTASSIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 20% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.86 Å R-free 0.218
3P1E Crystal structure of the bromodomain of human CREBBP in complex with dimethyl sulfoxide (DMSO) 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：Bromo domain, UNP residues 1081-1197	未记录	SCN THIOCYANATE ION × 1 DMS DIMETHYL SULFOXIDE × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.80 Å R-free 0.236
3P1E Crystal structure of the bromodomain of human CREBBP in complex with dimethyl sulfoxide (DMSO) 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：Bromo domain, UNP residues 1081-1197	未记录	DMS DIMETHYL SULFOXIDE × 1 K POTASSIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.80 Å R-free 0.236
3P1F Crystal structure of the bromodomain of human CREBBP in complex with a hydroquinazolin ligand 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：Bromo domain, UNP residues 1081-1197	未记录	EDO 1,2-ETHANEDIOL × 3 K POTASSIUM ION × 1 3PF 3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN 20% PEG3350 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.63 Å R-free 0.218
3P1F Crystal structure of the bromodomain of human CREBBP in complex with a hydroquinazolin ligand 提交 2010-09-30	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：Bromo domain, UNP residues 1081-1197	未记录	EDO 1,2-ETHANEDIOL × 5 K POTASSIUM ION × 1 3PF 3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN 20% PEG3350 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.63 Å R-free 0.218
3SVH Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand 提交 2011-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	KRG 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-ethoxybenzoic acid × 2 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.25M KSCN, 10% PEG 3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.80 Å R-free 0.224
3SVH Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand 提交 2011-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	KRG 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-ethoxybenzoic acid × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.25M KSCN, 10% PEG 3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.80 Å R-free 0.224
4A9K BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide 提交 2011-11-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：BROMODOMAIN, RESIDUES 1081-1197	未记录	EDO 1,2-ETHANEDIOL × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 SCN THIOCYANATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 277 K；150 MM KSCN, 20% PEG 3350, 4 DEGREES CELSIUS.	分辨率 1.81 Å R-free 0.197
4A9K BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide 提交 2011-11-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：BROMODOMAIN, RESIDUES 1081-1197	未记录	TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 K POTASSIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 277 K；150 MM KSCN, 20% PEG 3350, 4 DEGREES CELSIUS.	分辨率 1.81 Å R-free 0.197
4N3W Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in complex with Acetylated Histone 4 Peptide (H4K20ac). 提交 2013-10-07	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 1080–1316（237 aa）片段：Bromodomain-PHD Finger Module, residues 1080-1316	未记录	ZN ZINC ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；25% PEG 3,350, 0.2 M magnesium chloride, and 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K	分辨率 1.90 Å R-free 0.286
4N4F Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in complex with di-Acetylated Histone 4 Peptide (H412acK16ac). 提交 2013-10-08	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 1080–1316（237 aa）片段：Bromodomain residues 1080-1316	未记录	ZN ZINC ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% PEG MME 2,000, 0.2 M trimethylamine N-oxide, and 0.1 M Tris, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K	分辨率 1.83 Å R-free 0.241
4NR4 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand 提交 2013-11-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	2LK 1-(4-chlorobenzyl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazole × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；0.1M MgCl, 0.1M Tris pH 8.0, 20% PEG 6K, 10% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.69 Å R-free 0.192
4NR4 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand 提交 2013-11-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	2LK 1-(4-chlorobenzyl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazole × 2 EDO 1,2-ETHANEDIOL × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；0.1M MgCl, 0.1M Tris pH 8.0, 20% PEG 6K, 10% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.69 Å R-free 0.192
4NR5 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand 提交 2013-11-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	2LL 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-(2-phenylethyl)-1H-benzimidazole × 1 NO3 NITRATE ION × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.20M NaNO3, 20.0% PEG 3350, 10.0% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.66 Å R-free 0.226
4NR6 Crystal structure of the bromodomain of human CREBBP in complex with an oxazepin ligand 提交 2013-11-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	2LN 1-[7-(3,4-dimethoxyphenyl)-9-{[(3R)-1-methylpiperidin-3-yl]methoxy}-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]propan-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6；277 K；0.10M MgCl2, 0.1M MES pH 6.0, 20.0% PEG 6K, 10.0% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.66 Å R-free 0.231
4NR7 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand 提交 2013-11-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	EDO 1,2-ETHANEDIOL × 3 2LO 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6；277 K；0.20M NH4Cl, 0.1M MES pH 6.0, 20.0% PEG 6K, 10.0% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.20 Å R-free 0.144
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand 提交 2013-12-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.83 Å R-free 0.251
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand 提交 2013-12-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.83 Å R-free 0.251
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand 提交 2013-12-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.83 Å R-free 0.251
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand 提交 2013-12-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.83 Å R-free 0.251
4NYW Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand 提交 2013-12-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	SCN THIOCYANATE ION × 1 2O3 (3R)-N-[3-(3,4-dihydroquinolin-1(2H)-yl)propyl]-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-5-carboxamide × 1 EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；20% PEG 3350, 9% Ethylene Glycol, 0.18M KSCN, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.43 Å R-free 0.187
4NYX Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand 提交 2013-12-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	2O4 (3R)-N-[3-(7-methoxy-3,4-dihydroquinolin-1(2H)-yl)propyl]-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-5-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；0.05M CaCl2, 0.1M TRIS, 20.0% PEG 6K, 10.0% EtGly, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.10 Å R-free 0.135
4OUF Crystal Structure of CBP bromodomain 提交 2014-02-17	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：Bromo domain: residues 1082-1197	未记录	PEG DI(HYDROXYETHYL)ETHER × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1 M HEPES-Na pH 7.0, 0.2M KSCN, 25% PEG3350 and 5% Ethylene Glycol, VAPOR DIFFUSION, HANGING DROP, temperature 277K	分辨率 1.40 Å R-free 0.191
4OUF Crystal Structure of CBP bromodomain 提交 2014-02-17	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：Bromo domain: residues 1082-1197	未记录	EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1 M HEPES-Na pH 7.0, 0.2M KSCN, 25% PEG3350 and 5% Ethylene Glycol, VAPOR DIFFUSION, HANGING DROP, temperature 277K	分辨率 1.40 Å R-free 0.191
4TQN Crystal structure of the bromodomain of human CREBBP in complex with UL04 提交 2014-06-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：Monomeric	链 A 1081–1197（117 aa）片段：Kinase domain, Residues 1081-1197	未记录	UL4 3-[(5-acetyl-2-ethoxyphenyl)carbamoyl]benzoic acid × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M MES pH 6.5, 0.1M MgCl2, 20% PEG 6000, 10% EtGly	分辨率 1.70 Å R-free 0.199
4TS8 Crystal structure of the bromodomain of human CREBBP in complex with XZ08 提交 2014-06-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：Monomeric	链 A 1081–1197（117 aa）片段：Kinase domain, residues 1081-1197	未记录	EDO 1,2-ETHANEDIOL × 2 XZ8 4-(1-acetyl-1H-indol-3-yl)-5-methyl-1,2-dihydro-3H-pyrazol-3-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M MES pH 6.5, 0.1M MgCl2, 20% PEG 3350 10% EtGly	分辨率 2.00 Å R-free 0.254
4WHU BROMO domain of CREB binding protein 提交 2014-09-23	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	3OT 2-methoxy-4-{1-[2-(morpholin-4-yl)ethyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl}cyclohepta-2,4,6-trien-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；obtained through screen with Hampton Research kits (HT and Index)	分辨率 2.11 Å R-free 0.261
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 提交 2015-03-03	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1045–1158（114 aa）片段：bromodomain	未记录	986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride	分辨率 1.65 Å R-free 0.269
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 提交 2015-03-03	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1045–1158（114 aa）片段：bromodomain	未记录	986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride	分辨率 1.65 Å R-free 0.269
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 提交 2015-03-03	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1045–1158（114 aa）片段：bromodomain	未记录	986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride	分辨率 1.65 Å R-free 0.269
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 提交 2015-03-03	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1045–1158（114 aa）片段：bromodomain	未记录	986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride	分辨率 1.65 Å R-free 0.269
5CGP Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory cytokines in macrophages and RGS4 in neurons 提交 2015-07-09	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	53W 5-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[2-(4-methoxyphenyl)ethyl]-1-[2-(morpholin-4-yl)ethyl]-1H-benzimidazole × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；15-20% PEG 8000, 0.2M CaAcetate, 0.1 M cacodylate ph 6-7	分辨率 1.96 Å R-free 0.249
5DBM Crystal structure of the CBP bromodomain in complex with CPI703 提交 2015-08-21	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	58N (4R)-6-(1-tert-butyl-1H-pyrazol-4-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)	分辨率 1.86 Å R-free 0.220
5DBM Crystal structure of the CBP bromodomain in complex with CPI703 提交 2015-08-21	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	58N (4R)-6-(1-tert-butyl-1H-pyrazol-4-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)	分辨率 1.86 Å R-free 0.220
5DBM Crystal structure of the CBP bromodomain in complex with CPI703 提交 2015-08-21	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	58N (4R)-6-(1-tert-butyl-1H-pyrazol-4-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)	分辨率 1.86 Å R-free 0.220
5EIC Crystal structure of the bromodomain of human CREBBP in complex with AYC 提交 2015-10-29	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.50 Å R-free 0.209
5EIC Crystal structure of the bromodomain of human CREBBP in complex with AYC 提交 2015-10-29	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	5J5 2-[(chloroacetyl)amino]-5-[(E)-(4-sulfophenyl)diazenyl]benzenesulfonic acid × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.50 Å R-free 0.209
5ENG Crystal structure of the bromodomain of human CREBBP in complex with UP39 提交 2015-11-09	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	5QN methyl 2-[2-(3,5-dihydro-2~{H}-pyrazin-4-yl)ethoxy]-5-[(5-ethanoyl-2-ethoxy-phenyl)carbamoyl]benzoate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.30 Å R-free 0.172
5EP7 Crystal structure of the bromodomain of human CREBBP in complex with UN32 提交 2015-11-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	5QR 3-[(1-methyl-6-oxidanylidene-pyridin-3-yl)carbonylamino]benzoic acid × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.20 Å R-free 0.176
5GH9 Crystal structure of CBP Bromodomain with H3K56ac peptide 提交 2016-06-19	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 1081–1196（116 aa）片段：UNP residues 1081-1196	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.05 M Cadmium sulfate hydrate, 0.1 M HEPES, 1.0 M Sodium acetate trihydrate,	分辨率 1.45 Å R-free 0.176
5H85 Crystal structure of the bromodomain of human CREBBP in complex with UO37D 提交 2015-12-23	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	5XS methyl 3-(7~{H}-purin-6-ylcarbamoyl)benzoate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.15M KSCN, 20% PEG 3350, 10% EtGly	分辨率 1.70 Å R-free 0.199
5I83 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02773986 提交 2016-02-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	SCN THIOCYANATE ION × 1 68Y (4R)-4-methyl-7-[(1R)-1-phenylethoxy]-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.35 Å R-free 0.188
5I86 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02778174 提交 2016-02-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	EDO 1,2-ETHANEDIOL × 1 SCN THIOCYANATE ION × 1 69A (4R)-N-benzyl-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-6-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.05 Å R-free 0.161
5I86 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02778174 提交 2016-02-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	EDO 1,2-ETHANEDIOL × 1 69A (4R)-N-benzyl-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-6-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.05 Å R-free 0.161
5I89 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02857790 提交 2016-02-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	ACT ACETATE ION × 1 CA CALCIUM ION × 1 69B (4R)-6-(3-cyclopropyl-1-methyl-1H-indazol-5-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M calcium acetate hydrate, and 20% w/v PEG3350	分辨率 1.07 Å R-free 0.137
5I8B CBP in complex with Cpd23 ((R)-6-(3-(benzyloxy)phenyl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one) 提交 2016-02-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1312（232 aa）	未记录	ZN ZINC ION × 3 69F (4R)-6-[3-(benzyloxy)phenyl]-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 EDO 1,2-ETHANEDIOL × 5 NA SODIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 8, 0.2 M sodium thiocyanate 19-23% PEG 3350	分辨率 1.52 Å R-free 0.200
5I8G CBP in complex with Cpd637 ((R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one) 提交 2016-02-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1312（232 aa）	未记录	ZN ZINC ION × 3 69E (4R)-4-methyl-6-[1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 EDO 1,2-ETHANEDIOL × 5 NA SODIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；containing 0.1 M Bis-Tris pH 8, 0.2 M sodium thiocyanate 19-23% PEG 3350	分辨率 1.41 Å R-free 0.210
5J0D Crystal structure of the bromodomain of human CREBBP in complex with a benzoxazepine compound 提交 2016-03-28	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	6F9 7-(3,5-dimethoxyphenyl)-N-[(3S)-1-methylpiperidin-3-yl]-4-propanoyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-carboxamide × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 7.5；277 K；25% PEG3350, 0.2 M MgCl2, 0.1M BisTris pH 7.5	分辨率 1.05 Å R-free 0.197
5JEM Complex of IRF-3 with CBP 提交 2016-04-18	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 C 2065–2111（47 aa）片段：UNP residues 2065-2111 链 D 2065–2111（47 aa）片段：UNP residues 2065-2111	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3350	分辨率 2.50 Å R-free 0.242
5JEM Complex of IRF-3 with CBP 提交 2016-04-18	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白异源复合物异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 F 2065–2111（47 aa）片段：UNP residues 2065-2111 链 H 2065–2111（47 aa）片段：UNP residues 2065-2111	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3350	分辨率 2.50 Å R-free 0.242
5KTU Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold 提交 2016-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	6XB 1-(3-phenylazanyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M magnesium chloride, 0.1 M Bis-Tris pH 6.5, and 25% polyethylene glycol (PEG) 3350	分辨率 1.38 Å R-free 0.212
5KTU Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold 提交 2016-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：bromodomain (UNP residues 1082-1197)	未记录	DMS DIMETHYL SULFOXIDE × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M magnesium chloride, 0.1 M Bis-Tris pH 6.5, and 25% polyethylene glycol (PEG) 3350	分辨率 1.38 Å R-free 0.212
5KTW CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide) 提交 2016-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	6XG 3-[[1-(cyclopropylmethyl)-5-ethanoyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-3-yl]amino]-~{N}-propan-2-yl-benzamide × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350	分辨率 1.09 Å R-free 0.176
5KTW CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide) 提交 2016-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	6XG 3-[[1-(cyclopropylmethyl)-5-ethanoyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-3-yl]amino]-~{N}-propan-2-yl-benzamide × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350	分辨率 1.09 Å R-free 0.176
5KTW CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide) 提交 2016-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	6XG 3-[[1-(cyclopropylmethyl)-5-ethanoyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-3-yl]amino]-~{N}-propan-2-yl-benzamide × 1 EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350	分辨率 1.09 Å R-free 0.176
5KTX CREBBP bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone) 提交 2016-07-12	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	6XH 1-[3-[[2-fluoranyl-4-(1-methylpyrazol-4-yl)phenyl]amino]-1-[(3~{S})-oxolan-3-yl]-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-5-yl]ethanone × 1 EDO 1,2-ETHANEDIOL × 2 DMS DIMETHYL SULFOXIDE × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 5.5；287 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350	分辨率 1.27 Å R-free 0.172
5LPJ Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM1 提交 2016-08-13	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	XDM ~{N}-[(3-chlorophenyl)methyl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 EVAPORATION；pH 6.5；277 K；LiSO4, PEG 3350	分辨率 1.65 Å R-free 0.196
5LPL Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM3c 提交 2016-08-13	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	71X ~{N}-[(1~{R},2~{R})-7-chloranyl-2-oxidanyl-1,2,3,4-tetrahydronaphthalen-1-yl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 EVAPORATION；pH 7.5；277 K；NaCl, PEG 3350	分辨率 1.65 Å R-free 0.210
5MME Crystal structure of CREBBP bromodomain complexd with US46C 提交 2016-12-09	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	8Q6 dimethyl 5-[(5-ethanoyl-2-ethoxy-phenyl)amino]benzene-1,3-dicarboxylate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Cacodylate, pH6.5, 0.2 M Calcium acetate, 18% PEG8000	分辨率 1.35 Å R-free 0.176
5MME Crystal structure of CREBBP bromodomain complexd with US46C 提交 2016-12-09	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	8Q6 dimethyl 5-[(5-ethanoyl-2-ethoxy-phenyl)amino]benzene-1,3-dicarboxylate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Cacodylate, pH6.5, 0.2 M Calcium acetate, 18% PEG8000	分辨率 1.35 Å R-free 0.176
5MMG Crystal structure of CREBBP bromodomain complexed with UT07C 提交 2016-12-09	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	UT0 1-[4-ethoxy-3-[(1-methylsulfonylindol-6-yl)amino]phenyl]ethanone × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 10% Ethylene Glycol, 20% PEG3350	分辨率 1.23 Å R-free 0.163
5MPK Crystal structure of CREBBP bromodomain complexed with DK19 提交 2016-12-16	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	0BC ~{N}-(5-ethanoyl-2-ethoxy-phenyl)-3-(2~{H}-1,2,3,4-tetrazol-5-yl)-5-(1,3-thiazol-4-yl)benzamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.1 M HEPES-Na, pH7.5, 0.2 M MgCl2, 25% P3350	分辨率 1.90 Å R-free 0.239
5MPK Crystal structure of CREBBP bromodomain complexed with DK19 提交 2016-12-16	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	0BC ~{N}-(5-ethanoyl-2-ethoxy-phenyl)-3-(2~{H}-1,2,3,4-tetrazol-5-yl)-5-(1,3-thiazol-4-yl)benzamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.1 M HEPES-Na, pH7.5, 0.2 M MgCl2, 25% P3350	分辨率 1.90 Å R-free 0.239
5MPN Crystal structure of CREBBP bromodomain complexed with FA26 提交 2016-12-16	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	YE5 1-[4-ethoxy-3-[3-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]ethanone × 2 EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.2 M MgCl2, 0.1 M Bis-Tris, pH6.5, 5% EG, 23% PEG3350	分辨率 1.23 Å R-free 0.167
5MPZ Crystal structure of CREBBP bromodomain complexed with CBP007 提交 2016-12-19	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	4I8 methyl 2-oxidanylidene-3~{H}-1,3-benzoxazole-6-carboxylate × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M MgCl2, 0.1 M Bis-Tris, pH 6.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.40 Å R-free 0.176
5MQE Crystal structure of CREBBP bromodomain complexed with CBP006 提交 2016-12-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	PKU 4-bromanyl-~{N}-methyl-1~{H}-pyrrole-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.65 Å R-free 0.225
5MQE Crystal structure of CREBBP bromodomain complexed with CBP006 提交 2016-12-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	PKU 4-bromanyl-~{N}-methyl-1~{H}-pyrrole-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.65 Å R-free 0.225
5MQG Crystal structure of CREBBP bromodomain complexed with CBP015 提交 2016-12-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	F31 1-(4-azanyl-3-methoxy-phenyl)ethanone × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.35 Å R-free 0.191
5MQG Crystal structure of CREBBP bromodomain complexed with CBP015 提交 2016-12-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	F31 1-(4-azanyl-3-methoxy-phenyl)ethanone × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350	分辨率 1.35 Å R-free 0.191
5MQK Crystal structure of CREBBP bromodomain complexed with CBP019 提交 2016-12-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	QPR 1-(1-methylindol-3-yl)ethanone × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG	分辨率 1.53 Å R-free 0.210
5MQK Crystal structure of CREBBP bromodomain complexed with CBP019 提交 2016-12-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	QPR 1-(1-methylindol-3-yl)ethanone × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG	分辨率 1.53 Å R-free 0.210
5NLK Crystal structure of CREBBP bromodomain complexd with US13A 提交 2017-04-04	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	92E ~{N}-[3-acetamido-5-[(5-ethanoyl-2-ethoxy-phenyl)carbamoyl]phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Buffer System 3, pH8.5, 37.50% v/v MPD_P1K_P3350, 0.09 M NPS	分辨率 1.80 Å R-free 0.216
5NRW Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM4 提交 2017-04-25	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain, UNP residues 1081-1197	未记录	96N 4-ethanoyl-3-ethyl-5-methyl-~{N}-(naphthalen-1-ylmethyl)-1~{H}-pyrrole-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 4	X-RAY DIFFRACTION X-ray结晶条件 EVAPORATION；pH 6.5；277 K；LiSO4, PEG 3350, ethylene glycol	分辨率 1.70 Å R-free 0.260
5NU3 Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM-CBP 提交 2017-04-28	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain	未记录	99E ~{N}-[[2,8-bis(oxidanyl)naphthalen-1-yl]methyl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide × 1 BU3 (R,R)-2,3-BUTANEDIOL × 4 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 EVAPORATION；pH 6.5；277 K；LiSO4, PEG 3350, ethylene glycol	分辨率 1.75 Å R-free 0.200
5OWK Crystal structure of CREBBP bromodomain complexed with DSPB2A002 提交 2017-09-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	7MX ethyl 4-chloranyl-1-methyl-6-oxidanylidene-pyridine-3-carboxylate × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M MES, pH6.5, 0.1 M MgCl2, 20% PEG6K, 10% EG	分辨率 1.25 Å R-free 0.176
5SVH Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera 提交 2016-08-06	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 信息不足异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 587–673（87 aa）片段：UNP residues 587-673	未记录	GOL GLYCEROL × 2 CL CHLORIDE ION × 7	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M potassium sulfate 2.3M Ammonium sulphate	分辨率 2.05 Å R-free 0.242
5SVH Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera 提交 2016-08-06	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 信息不足异源复合物；蛋白 × 12 PDB 声明：dodecameric	链 A 587–673（87 aa）片段：UNP residues 587-673	未记录	GOL GLYCEROL × 12 CL CHLORIDE ION × 42	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M potassium sulfate 2.3M Ammonium sulphate	分辨率 2.05 Å R-free 0.242
5SVH Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera 提交 2016-08-06	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 信息不足异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 A 587–673（87 aa）片段：UNP residues 587-673	未记录	GOL GLYCEROL × 4 CL CHLORIDE ION × 14	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M potassium sulfate 2.3M Ammonium sulphate	分辨率 2.05 Å R-free 0.242
5TB6 Structure of bromodomain of CREBBP with a pyrazolo[4,3-c]pyridin fragment 提交 2016-09-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	77X 1-(3-phenyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)propan-1-one × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN 15% PEG 3350 5% EtGly	分辨率 1.79 Å R-free 0.243
5W0E CREBBP bromodomain in complex with Cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide) 提交 2017-05-30	配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：Bromodomain, UNP residues 1082-1197	未记录	9U4 3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350	分辨率 1.41 Å R-free 0.260
5W0F CREBBP Bromodomain in complex with Cpd3 ((S)-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydrofuran-3-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) 提交 2017-05-30	配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：Bromodomain, UNP residues 1082-1197	未记录	9U7 1-{3-[6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-[(3S)-oxolan-3-yl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350	分辨率 1.60 Å R-free 0.206
5W0Q CREBBP Bromodomain in complex with Cpd17 (N,2,7-trimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide) 提交 2017-05-31	配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：Bromodomain, UNP residues 1082-1197	未记录	SO4 SULFATE ION × 3 9UG (2R)-N,2,7-trimethyl-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.1M Bis-Tris pH 6.5, 0.2M Li2SO4, 25% PEG3350	分辨率 1.70 Å R-free 0.213
5XXH Crystal Structure Analysis of the CBP 提交 2017-07-04	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	E0D (3S)-1-[2-(3-ethanoylindol-1-yl)ethanoyl]piperidine-3-carboxylic acid × 1 EDO 1,2-ETHANEDIOL × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；30% PEG 3350, 0.2M MgCl2, 0.1M Tris HCl, PH 8.5	分辨率 1.62 Å R-free 0.208
6ALB CREBBP bromodomain in complex with Cpd 30 (1-(3-(3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) 提交 2017-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1312（232 aa）片段：Bromodomain (UNP residue 1081-1312)	未记录	ZN ZINC ION × 3 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 BKJ 1-{3-[3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350	分辨率 2.05 Å R-free 0.242
6ALC CREBBP bromodomain in complex with Cpd 4 (1-(1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) 提交 2017-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1085–1196（112 aa）片段：Bromodomain (UNP residues 1085-1196)	未记录	DMS DIMETHYL SULFOXIDE × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350	分辨率 1.39 Å R-free 0.212
6ALC CREBBP bromodomain in complex with Cpd 4 (1-(1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) 提交 2017-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1085–1196（112 aa）片段：Bromodomain (UNP residues 1085-1196)	未记录	BKD 1-[1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]ethan-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350	分辨率 1.39 Å R-free 0.212
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) 提交 2017-09-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	DMS DIMETHYL SULFOXIDE × 2 C2Y methyl 1H-indole-3-carboxylate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol	分辨率 1.30 Å R-free 0.216
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) 提交 2017-09-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	DMS DIMETHYL SULFOXIDE × 1 C2Y methyl 1H-indole-3-carboxylate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol	分辨率 1.30 Å R-free 0.216
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) 提交 2017-09-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	DMS DIMETHYL SULFOXIDE × 2 C2Y methyl 1H-indole-3-carboxylate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol	分辨率 1.30 Å R-free 0.216
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) 提交 2017-09-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1085–1196（112 aa）片段：bromodomain (UNP residues 1085-1196)	未记录	DMS DIMETHYL SULFOXIDE × 1 C2Y methyl 1H-indole-3-carboxylate × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol	分辨率 1.30 Å R-free 0.216
6AY3 CREBBP bromodomain in complex with Cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1H-indole-3-carboxamide) 提交 2017-09-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1083–1197（115 aa）片段：Bromodomain (UNP residue 1083-1197)	未记录	C3J 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1H-indole-3-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 NA SODIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350	分辨率 1.39 Å R-free 0.237
6AY3 CREBBP bromodomain in complex with Cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1H-indole-3-carboxamide) 提交 2017-09-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1083–1197（115 aa）片段：Bromodomain (UNP residue 1083-1197)	未记录	C3J 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1H-indole-3-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350	分辨率 1.39 Å R-free 0.237
6AY5 CREBBP bromodomain in complex with Cpd17 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-3-methylbenzo[d]thiazol-2(3H)-one) 提交 2017-09-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1083–1197（115 aa）片段：Bromodomain (UNP residue 1083-1197)	未记录	C3V 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-3-methyl-1,3-benzothiazol-2(3H)-one × 1 SO4 SULFATE ION × 2 DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350	分辨率 1.44 Å R-free 0.184
6DMK A multiconformer ligand model of an isoxazolyl-benzimidazole ligand bound to the bromodomain of human CREBBP 提交 2018-06-05	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1045–1157（113 aa）	未记录	NO3 NITRATE ION × 1 2LL 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-(2-phenylethyl)-1H-benzimidazole × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.20M NaNO3, 20.0% PEG 3350, 10.0% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K	分辨率 1.66 Å R-free 0.234
6ES7 Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins 提交 2017-10-19	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 B 2061–2109（49 aa）	未记录	未记录非水小分子	SOLUTION NMR NMR测量条件 pH 6.5；298 K；离子强度（mmCIF原始值）na；压力 1 NMR样品组成 100 % 13C/15N CID, 100 % 13C/15N NCBD, 90% H2O/10% D2O \| 90% H2O/10% D2O	分辨率未提供
6FQO Crystal structure of CREBBP bromodomain complexd with DT29 提交 2018-02-14	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	E2T ~{N}-[3-(2,5-dimethyl-3-oxidanylidene-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG	分辨率 1.35 Å R-free 0.194
6FQO Crystal structure of CREBBP bromodomain complexd with DT29 提交 2018-02-14	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	E2T ~{N}-[3-(2,5-dimethyl-3-oxidanylidene-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG	分辨率 1.35 Å R-free 0.194
6FQT Crystal structure of CREBBP bromodomain complexd with DR46 提交 2018-02-14	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	AY2 ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(1-methylpyrazol-3-yl)phenyl]furan-2-carboxamide × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350	分辨率 1.80 Å R-free 0.255
6FQU Crystal structure of CREBBP bromodomain complexd with DR09 提交 2018-02-14	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	E3B 1-[3-[3-[3,3-bis(fluoranyl)piperidin-1-yl]phenyl]-4-ethoxy-phenyl]ethanone × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG	分辨率 1.43 Å R-free 0.190
6FR0 Crystal structure of CREBBP bromodomain complexd with PB08 提交 2018-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	E3H ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(2-ethyl-5-methyl-3-oxidanylidene-1,2-oxazol-4-yl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350	分辨率 1.50 Å R-free 0.202
6FR0 Crystal structure of CREBBP bromodomain complexd with PB08 提交 2018-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	E3H ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(2-ethyl-5-methyl-3-oxidanylidene-1,2-oxazol-4-yl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350	分辨率 1.50 Å R-free 0.202
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 提交 2018-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate	分辨率 2.10 Å R-free 0.228
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 提交 2018-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate	分辨率 2.10 Å R-free 0.228
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 提交 2018-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）	未记录	E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate	分辨率 2.10 Å R-free 0.228
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 提交 2018-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1081–1197（117 aa）	未记录	E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate	分辨率 2.10 Å R-free 0.228
6QST Structure of CREBBP bromodomain with compound 2 bound 提交 2019-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350	分辨率 2.10 Å R-free 0.219
6QST Structure of CREBBP bromodomain with compound 2 bound 提交 2019-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350	分辨率 2.10 Å R-free 0.219
6QST Structure of CREBBP bromodomain with compound 2 bound 提交 2019-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）	未记录	JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350	分辨率 2.10 Å R-free 0.219
6QST Structure of CREBBP bromodomain with compound 2 bound 提交 2019-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1081–1197（117 aa）	未记录	JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350	分辨率 2.10 Å R-free 0.219
6SQC Crystal structure of complex between nuclear coactivator binding domain of CBP and [1040-1086]ACTR containing alpha-methylated Leu1055 and Leu1076 提交 2019-09-03	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 信息不足异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 2061–2112（52 aa）	未记录	EDO 1,2-ETHANEDIOL × 1 ZN ZINC ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；298 K；20% PEG6000, 100 mM Tris pH 8 and 10 mM ZnCl2	分辨率 2.28 Å R-free 0.274
6SQE Crystal structure of CREBBP bromodomain complexed with KD341 提交 2019-09-03	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	LSZ ~{N}-[3-[(5-ethanoyl-2-ethoxy-phenyl)carbamoyl]-5-(1-methylpyrazol-3-yl)phenyl]-5-[(4-methylpiperazin-1-yl)methyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2M MgCl2, 25% PEG 3350, 0.1M BisTris pH 5.5	分辨率 1.51 Å R-free 0.191
6SQF Crystal structure of CREBBP bromodomain complexed with LB32A 提交 2019-09-03	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	LTW ~{N}-[3-[[5-ethanoyl-2-[2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy]phenyl]carbamoyl]-5-(1-methylpyrazol-3-yl)phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；0.1M MES pH 6.5, 12% PEG 20000	分辨率 2.01 Å R-free 0.215
6SQM Crystal structure of CREBBP bromodomain complexed with LA36 提交 2019-09-04	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	LU5 ~{N}-[3-acetamido-5-[(3-methylcinnolin-5-yl)carbamoyl]phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；8% Ethylene glycol, 0.1M HEPES pH 7.5, 10% PEG 8000	分辨率 1.80 Å R-free 0.269
6SQM Crystal structure of CREBBP bromodomain complexed with LA36 提交 2019-09-04	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	LU5 ~{N}-[3-acetamido-5-[(3-methylcinnolin-5-yl)carbamoyl]phenyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；8% Ethylene glycol, 0.1M HEPES pH 7.5, 10% PEG 8000	分辨率 1.80 Å R-free 0.269
6SQM Crystal structure of CREBBP bromodomain complexed with LA36 提交 2019-09-04	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）	未记录	LU5 ~{N}-[3-acetamido-5-[(3-methylcinnolin-5-yl)carbamoyl]phenyl]furan-2-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277.15 K；8% Ethylene glycol, 0.1M HEPES pH 7.5, 10% PEG 8000	分辨率 1.80 Å R-free 0.269
6SXX Crystal structure of the bromodomain of human CREBBP in complex with ACA007 提交 2019-09-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	EDO 1,2-ETHANEDIOL × 2 LXQ (3~{R})-1-ethanoylpyrrolidine-3-carboxylic acid × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；25% PEG3350, 0.2 M Potassium thiocyanate, 5% EtGly	分辨率 2.01 Å R-free 0.253
6SXX Crystal structure of the bromodomain of human CREBBP in complex with ACA007 提交 2019-09-26	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	EDO 1,2-ETHANEDIOL × 1 LXQ (3~{R})-1-ethanoylpyrrolidine-3-carboxylic acid × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；277 K；25% PEG3350, 0.2 M Potassium thiocyanate, 5% EtGly	分辨率 2.01 Å R-free 0.253
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride	分辨率 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride	分辨率 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）	未记录	OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride	分辨率 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1081–1197（117 aa）	未记录	OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride	分辨率 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 5 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 E 1081–1197（117 aa）	未记录	OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride	分辨率 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 6 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 F 1081–1197（117 aa）	未记录	OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride	分辨率 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 7 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 G 1081–1197（117 aa）	未记录	OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride	分辨率 2.20 Å R-free 0.269
6YIK Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；21% PEG3350 15% ethylene glycol 0.25M sodium formate	分辨率 1.70 Å R-free 0.184
6YIK Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；21% PEG3350 15% ethylene glycol 0.25M sodium formate	分辨率 1.70 Å R-free 0.184
6YIK Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）	未记录	OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；21% PEG3350 15% ethylene glycol 0.25M sodium formate	分辨率 1.70 Å R-free 0.184
6YIL Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；20% PEG3350 10% ethylene glycol 0.2M sodium acetate	分辨率 1.22 Å R-free 0.151
6YIM Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand 提交 2020-04-01	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	OS8 (4~{R})-~{N}-[3-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)propyl]-4-methyl-2-oxidanylidene-1,3,4,5-tetrahydro-1,5-benzodiazepine-6-carboxamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；20% PEG3350 10% ethylene glycol 0.2M sodium fluoride	分辨率 1.23 Å R-free 0.167
7CO1 Crystal structure of SMAD2 in complex with wild-type CBP 提交 2020-08-03	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 6 PDB 声明：hexameric	链 B 1951–1973（23 aa）链 D 1951–1973（23 aa）链 F 1951–1973（23 aa）	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；1 M sodium phosphate monobasic monohydrate-potassium phosphate dibasic	分辨率 3.30 Å R-free 0.283
7EVJ Crystal structure of CBP bromodomain liganded with 9c 提交 2021-05-21	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	JE9 3-acetyl-1-((3-(1-cyclopropyl-1H-pyrazol-4-yl)-2-fluoro-5-(hydroxymethyl)phenyl)carbamoyl)indolizin-7-yl dimethylcarbamate × 1 PO4 PHOSPHATE ION × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 4.6；277 K；0.2 M NH4H2PO4, 20% PEG 3350, pH 4.6, and 20% Gly	分辨率 2.57 Å R-free 0.209
7JFL Crystal structure of human phosphorylated IRF-3 bound to CBP 提交 2020-07-17	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 C 2065–2111（47 aa）链 D 2065–2111（47 aa）	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 5；277 K；0.1 M sodium acetate pH 5.0, 0.2 M MgCl2, 5% PEG 3350	分辨率 1.68 Å R-free 0.223
7JFM Crystal structure of mouse phosphorylated IRF-3 bound to CBP 提交 2020-07-17	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 C 2065–2111（47 aa）链 D 2065–2111（47 aa）	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.2 M ammonium citrate tribasic at pH 7.0, 12% PEG 3350	分辨率 2.23 Å R-free 0.252
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 5 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 F 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 6 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 G 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 7 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 H 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 提交 2020-08-20	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 8 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 E 1082–1197（116 aa）	未记录	YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4	分辨率 2.20 Å R-free 0.276
7RLE Crystal structure of PPAR gamma in complex with CREB-binding protein and agonist GW1929 提交 2021-07-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 B 57–80（24 aa）片段：Residues 57-80 链 D 57–80（24 aa）片段：Residues 57-80	未记录	EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6.5；293.15 K；1M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate, pH 6.5	分辨率 2.50 Å R-free 0.275
7TB3 cryo-EM structure of MBP-KIX-apoferritin 提交 2021-12-21	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 信息不足同源多聚体；蛋白 × 24 PDB 声明：24-meric	链 A 549–630（82 aa）链 B 549–630（82 aa）链 C 549–630（82 aa）链 D 549–630（82 aa）链 E 549–630（82 aa）链 F 549–630（82 aa）链 G 549–630（82 aa）链 H 549–630（82 aa）链 I 549–630（82 aa）链 J 549–630（82 aa）链 K 549–630（82 aa）链 L 549–630（82 aa）链 M 549–630（82 aa）链 N 549–630（82 aa）链 O 549–630（82 aa）链 P 549–630（82 aa）链 Q 549–630（82 aa）链 R 549–630（82 aa）链 S 549–630（82 aa）链 T 549–630（82 aa）链 U 549–630（82 aa）链 V 549–630（82 aa）链 W 549–630（82 aa）链 X 549–630（82 aa）	未记录	未记录非水小分子	ELECTRON MICROSCOPY cryo-EM缓冲液 pH 8 cryo-EM玻璃化条件冷冻剂 ETHANE	分辨率 2.57 Å
7TBH cryo-EM structure of MBP-KIX-apoferritin complex with peptide 7 提交 2021-12-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 信息不足异源复合物；蛋白 × 48 PDB 声明：48-meric	链 A 549–630（82 aa）链 B 549–630（82 aa）链 C 549–630（82 aa）链 D 549–630（82 aa）链 E 549–630（82 aa）链 F 549–630（82 aa）链 G 549–630（82 aa）链 H 549–630（82 aa）链 I 549–630（82 aa）链 J 549–630（82 aa）链 K 549–630（82 aa）链 L 549–630（82 aa）链 M 549–630（82 aa）链 N 549–630（82 aa）链 O 549–630（82 aa）链 P 549–630（82 aa）链 Q 549–630（82 aa）链 R 549–630（82 aa）链 S 549–630（82 aa）链 T 549–630（82 aa）链 U 549–630（82 aa）链 V 549–630（82 aa）链 W 549–630（82 aa）链 X 549–630（82 aa）	未记录	未记录非水小分子	ELECTRON MICROSCOPY cryo-EM缓冲液 pH 8 cryo-EM玻璃化条件冷冻剂 ETHANE	分辨率 2.30 Å
7WX2 CBP-BrD complexed with NEO2734 提交 2022-02-14	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：bromodomain	未记录	7OW 1,3-dimethyl-5-[2-(oxan-4-yl)-3-[2-(trifluoromethyloxy)ethyl]benzimidazol-5-yl]pyridin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 EVAPORATION；pH 8.5；289 K；PEG3350, NaNO3, ethylene glycol	分辨率 1.24 Å R-free 0.200
7XH6 Crystal structure of CBP bromodomain liganded with CCS1477 提交 2022-04-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	GOL GLYCEROL × 1 DMS DIMETHYL SULFOXIDE × 1 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.1M HEPES pH 7.5, 2% v/v Tacsimate pH 7.0, 20% w/v Polyethylene glycol 3350	分辨率 1.75 Å R-free 0.227
7XH6 Crystal structure of CBP bromodomain liganded with CCS1477 提交 2022-04-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.1M HEPES pH 7.5, 2% v/v Tacsimate pH 7.0, 20% w/v Polyethylene glycol 3350	分辨率 1.75 Å R-free 0.227
7XHE Crystal structure of CBP bromodomain liganded with CCS151 提交 2022-04-08	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	JHF (6S)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]-1-(3-fluoranyl-4-methoxy-phenyl)piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2M Sodium malonate pH 7.0, 20% w/v Polyethylene glycol 3350	分辨率 1.59 Å R-free 0.231
7XHE Crystal structure of CBP bromodomain liganded with CCS151 提交 2022-04-08	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	JHF (6S)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]-1-(3-fluoranyl-4-methoxy-phenyl)piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2M Sodium malonate pH 7.0, 20% w/v Polyethylene glycol 3350	分辨率 1.59 Å R-free 0.231
7XI0 Crystal structure of CBP bromodomain liganded with CCS150 提交 2022-04-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	EL0 (6S)-1-(3-chloranyl-4-methoxy-phenyl)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]piperidin-2-one × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2M NaAc, 20% w/v Polyethylene glycol, 3350 PH 7.3	分辨率 1.62 Å R-free 0.224
7XI0 Crystal structure of CBP bromodomain liganded with CCS150 提交 2022-04-11	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	EL0 (6S)-1-(3-chloranyl-4-methoxy-phenyl)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2M NaAc, 20% w/v Polyethylene glycol, 3350 PH 7.3	分辨率 1.62 Å R-free 0.224
7XIJ Crystal structure of CBP bromodomain liganded with Y08175 提交 2022-04-13	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1043–1159（117 aa）	未记录	EJ3 3-[(1-ethanoyl-5-methoxy-indol-3-yl)carbonylamino]-4-fluoranyl-5-(1-methylpyrazol-4-yl)benzoic acid × 1 DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2M MgCl2 0.1M TrsHCl 30% PEG4000 PH7.5	分辨率 1.82 Å R-free 0.221
7XM7 Crystal Structure of the CBP in complex with the Y08188 提交 2022-04-25	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	GAY 3-ethanoyl-~{N}-[2-fluoranyl-3-(1-methylpyrazol-4-yl)phenyl]-7-methoxy-indolizine-1-carboxamide × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2	分辨率 2.36 Å R-free 0.257
7XM7 Crystal Structure of the CBP in complex with the Y08188 提交 2022-04-25	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	GAY 3-ethanoyl-~{N}-[2-fluoranyl-3-(1-methylpyrazol-4-yl)phenyl]-7-methoxy-indolizine-1-carboxamide × 1 NO3 NITRATE ION × 1 DMS DIMETHYL SULFOXIDE × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2	分辨率 2.36 Å R-free 0.257
7XM7 Crystal Structure of the CBP in complex with the Y08188 提交 2022-04-25	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）	未记录	NO3 NITRATE ION × 1 PEG DI(HYDROXYETHYL)ETHER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2	分辨率 2.36 Å R-free 0.257
7XM7 Crystal Structure of the CBP in complex with the Y08188 提交 2022-04-25	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1081–1197（117 aa）	未记录	EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2	分辨率 2.36 Å R-free 0.257
7XNE Crystal structure of CBP bromodomain liganded with Y08284 提交 2022-04-28	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197 链 B 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	GHF N-[3-(1-cyclopropylpyrazol-4-yl)-2-fluoranyl-5-[(1S)-1-oxidanylethyl]phenyl]-3-ethanoyl-7-methoxy-indolizine-1-carboxamide × 2 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Magnesium acetate tetrahydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 20% w/v Polyethylene glycol 8,000	分辨率 2.17 Å R-free 0.259
7XNG Crystal structure of CBP bromodomain liganded with Y08092(31g) 提交 2022-04-28	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197 链 B 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	GI5 3-[(1-ethanoylindol-3-yl)carbonylamino]-5-[[(2S)-oxan-2-yl]oxymethyl]benzoic acid × 2 GOL GLYCEROL × 1 PEG DI(HYDROXYETHYL)ETHER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M KSCN 0.1M HEPES PH8.5	分辨率 2.35 Å R-free 0.242
8FUP Bromodomain of CBP liganded with BMS-536924 and CCS-1477 提交 2023-01-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain	未记录	N6I (3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one × 1 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；292 K；0.2 M Ammonium sulfate, 30% w/v Polyethylene glycol 8000	分辨率 1.70 Å R-free 0.212
8FUP Bromodomain of CBP liganded with BMS-536924 and CCS-1477 提交 2023-01-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：bromodomain	未记录	JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；292 K；0.2 M Ammonium sulfate, 30% w/v Polyethylene glycol 8000	分辨率 1.70 Å R-free 0.212
8FV2 Bromodomain of CBP liganded with CCS-1477 提交 2023-01-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain	未记录	PO4 PHOSPHATE ION × 3 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic	分辨率 1.87 Å R-free 0.226
8FV2 Bromodomain of CBP liganded with CCS-1477 提交 2023-01-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：bromodomain	未记录	PO4 PHOSPHATE ION × 2 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 2 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic	分辨率 1.87 Å R-free 0.226
8FV2 Bromodomain of CBP liganded with CCS-1477 提交 2023-01-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1082–1197（116 aa）片段：bromodomain	未记录	JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic	分辨率 1.87 Å R-free 0.226
8FV2 Bromodomain of CBP liganded with CCS-1477 提交 2023-01-18	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1082–1197（116 aa）片段：bromodomain	未记录	JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic	分辨率 1.87 Å R-free 0.226
8FXA Bromodomain of CBP liganded with iCBP4 提交 2023-01-24	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain	未记录	EDO 1,2-ETHANEDIOL × 3 YJY (6S)-1-[3,5-bis(trifluoromethyl)phenyl]-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 5.5；291 K；0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3350	分辨率 1.65 Å R-free 0.180
8FXA Bromodomain of CBP liganded with iCBP4 提交 2023-01-24	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：bromodomain	未记录	EDO 1,2-ETHANEDIOL × 1 YJY (6S)-1-[3,5-bis(trifluoromethyl)phenyl]-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 5.5；291 K；0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3350	分辨率 1.65 Å R-free 0.180
8FXE Bromodomain of CBP liganded with iCBP6 提交 2023-01-24	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP residues 1081-1197	未记录	YID (6S)-1-(3-tert-butylphenyl)-6-{(5P)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Sodium chloride, 0.1 M Tris pH 8.5, 25% w/v Polyethylene glycol 3350	分辨率 1.55 Å R-free 0.186
8FXN Bromodomain of CBP liganded with iCBP7 提交 2023-01-25	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain	未记录	YN0 tert-butyl {(1R,4s)-4-[(5M)-2-[(2S)-1-(3-tert-butylphenyl)-6-oxopiperidin-2-yl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazol-1-yl]cyclohexyl}carbamate × 1 EDO 1,2-ETHANEDIOL × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；292 K；0.03M Sodium nitrate, 0.03 Sodium phosphate dibasic, 0.03M Ammonium sulfate, 0.1 M Imidazole, 0.1 M MES pH 6.5, 20% v/v PEG 500 MME; 10% w/v PEG 20000	分辨率 2.00 Å R-free 0.242
8FXO Bromodomain of CBP liganded with iCBP8 提交 2023-01-25	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：bromodomain	未记录	YN5 (6S)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Sodium acetate trihydrate, 0.1 M TRIS hydrochloride pH 8.5, 30% w/v Polyethylene glycol 4000	分辨率 1.74 Å R-free 0.205
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 提交 2023-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）	未记录	YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000	分辨率 1.75 Å R-free 0.222
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 提交 2023-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）	未记录	YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000	分辨率 1.75 Å R-free 0.222
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 提交 2023-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1082–1197（116 aa）	未记录	YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 NI NICKEL (II) ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000	分辨率 1.75 Å R-free 0.222
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 提交 2023-02-15	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1082–1197（116 aa）	未记录	YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 NI NICKEL (II) ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000	分辨率 1.75 Å R-free 0.222
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 提交 2023-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1082–1197（116 aa）片段：Bromodomain, residues 1082-1197	未记录	EDO 1,2-ETHANEDIOL × 1 YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000	分辨率 1.85 Å R-free 0.225
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 提交 2023-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1082–1197（116 aa）片段：Bromodomain, residues 1082-1197	未记录	YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000	分辨率 1.85 Å R-free 0.225
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 提交 2023-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1082–1197（116 aa）片段：Bromodomain, residues 1082-1197	未记录	YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000	分辨率 1.85 Å R-free 0.225
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 提交 2023-02-22	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1082–1197（116 aa）片段：Bromodomain, residues 1082-1197	未记录	YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000	分辨率 1.85 Å R-free 0.225
8HAL Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 1 提交 2022-10-26	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白–DNA 异源复合物；蛋白 × 9 PDB 声明：undecameric	链 K 1084–1873（790 aa）	未记录	未记录非水小分子	ELECTRON MICROSCOPY cryo-EM缓冲液 pH 7.2 cryo-EM玻璃化条件冷冻剂 ETHANE	分辨率 4.40 Å
8HAM Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 2 提交 2022-10-26	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白–DNA 异源复合物；蛋白 × 9 PDB 声明：undecameric	链 K 1084–1873（790 aa）	未记录	未记录非水小分子	ELECTRON MICROSCOPY cryo-EM缓冲液 pH 7.2 cryo-EM玻璃化条件冷冻剂 ETHANE	分辨率 4.50 Å
8HAN Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 3 提交 2022-10-26	构建体不同聚集状态不同配体/离子不同实验方法不同实验环境不同结构质量不同	Assembly 1 蛋白–DNA 异源复合物；蛋白 × 9 PDB 声明：undecameric	链 K 1084–1873（790 aa）	未记录	未记录非水小分子	ELECTRON MICROSCOPY cryo-EM缓冲液 pH 7.2 cryo-EM玻璃化条件冷冻剂 ETHANE	分辨率 4.20 Å
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350	分辨率 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350	分辨率 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 1081–1197（117 aa）	未记录	SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350	分辨率 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 1081–1197（117 aa）	未记录	A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350	分辨率 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 5 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 E 1081–1197（117 aa）	未记录	A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350	分辨率 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 6 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 F 1081–1197（117 aa）	未记录	A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350	分辨率 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 7 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 G 1081–1197（117 aa）	未记录	A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 2 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350	分辨率 1.84 Å R-free 0.220
9GET Crystal structure of CREBBP bromodomain in complex with (R,E)-6-(5-(7-methoxy-3,4-dihydroquinolin-1(2H)-yl)pent-1-en-1-yl)-4-methyl-8-(morpholine-4-carbonyl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	A1IKM (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-8-morpholin-4-ylcarbonyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3,350	分辨率 1.29 Å R-free 0.167
9GEU Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	BU3 (R,R)-2,3-BUTANEDIOL × 2 A1IKL (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 3.5；277 K；0.1M citric acid, PEG 3350	分辨率 1.56 Å R-free 0.197
9GEU Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	BU3 (R,R)-2,3-BUTANEDIOL × 1 A1IKL (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione × 1 CIT CITRIC ACID × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 3.5；277 K；0.1M citric acid, PEG 3350	分辨率 1.56 Å R-free 0.197
9GEW Crystal structure of CREBBP bromodomain in complex with (R,E)-6-(5-(6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)pent-1-en-1-yl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	A1IKI (4~{R})-6-[(~{E})-5-(6-methoxy-2,3-dihydro-1,4-benzoxazin-4-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 BU3 (R,R)-2,3-BUTANEDIOL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；5% Tacsimate pH 7, 0.1 M Hepes pH 7, 10% PEG monomethyl ether 5000	分辨率 1.47 Å R-free 0.198
9GEY Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	A1IKK (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% PEG 3,350	分辨率 1.56 Å R-free 0.211
9GEY Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione 提交 2024-08-07	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1081–1197（117 aa）	未记录	A1IKK (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% PEG 3,350	分辨率 1.56 Å R-free 0.211
9H02 Crystal structure of human CREBBP histone acetyltransferase domain in complex with a bisubstrate inhibitor, Lys-CoA 提交 2024-10-07	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1322–1555（234 aa）链 A 1618–1700（83 aa）	突变：Y1503F 突变：Y1503F	01K [(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]methyl (3R,20R)-20-carbamoyl-3-hydroxy-2,2-dimethyl-4,8,14,22-tetraoxo-12-thia-5,9,15,21-tetraazatricos-1-yl dihydrogen diphosphate × 1 EDO 1,2-ETHANEDIOL × 6	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；291 K；0.1M (NH4)2SO4, 0.1 Na3 cit 5.6pH, 30% w/v PEG 4000	分辨率 2.03 Å R-free 0.224
9H0K Crystal structure of human CREBBP histone acetyltransferase domain in complex with Propionyl- Coenzyme A 提交 2024-10-08	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1322–1555（234 aa）链 A 1618–1700（83 aa）	突变：Y1503F 突变：Y1503F	1VU propionyl Coenzyme A × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；292 K；0.1M Na3 cit , 2.4M (NH4)2SO4	分辨率 1.75 Å R-free 0.240
9H0K Crystal structure of human CREBBP histone acetyltransferase domain in complex with Propionyl- Coenzyme A 提交 2024-10-08	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 1322–1555（234 aa）链 B 1618–1700（83 aa）	突变：Y1503F 突变：Y1503F	1VU propionyl Coenzyme A × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；292 K；0.1M Na3 cit , 2.4M (NH4)2SO4	分辨率 1.75 Å R-free 0.240
9IWL X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-CBP coactivator peptide co-crystals obtained by cross-seeding 提交 2024-07-25	构建体不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 B 62–80（19 aa）	未记录	PLM PALMITIC ACID × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；277 K；0.1M Tris (pH 8.5), 30% PEG 4000, 0.2M Sodium acetate trihydrate	分辨率 2.09 Å R-free 0.236
9J6O Crystal Structure of bromodomain of human CBP in complex with the inhibitor CZL-046 提交 2024-08-16	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）片段：UNP RESIDUES 1081-1197	未记录	A1L3S (3~{S},5~{S})-1-[3,4-bis(fluoranyl)phenyl]-5-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]-3-fluoranyl-pyrrolidin-2-one × 1 CL CHLORIDE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Potassium sulfate, 20% w/v Polyethylene glycol 3,350	分辨率 2.67 Å R-free 0.290
9JUU X-ray crystal structure of Y16515 in CBP 提交 2024-10-08	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	A1EDN (5~{S})-1-(3-chloranyl-4-methoxy-phenyl)-5-[4-(3-methyl-1,2-benzoxazol-5-yl)-1-[(2~{R})-2-morpholin-4-ylpropyl]imidazol-2-yl]pyrrolidin-2-one × 1 EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.2 M Sodium citrate tribasic dihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 30% v/v 2-Propanol	分辨率 1.48 Å R-free 0.219
9JUY X-ray crystal structure of Y16513 in CBP 提交 2024-10-08	构建体不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 1081–1197（117 aa）	未记录	A1EDO (5~{S})-1-(3-chloranyl-4-methoxy-phenyl)-5-[4-(3-methyl-1,2-benzoxazol-5-yl)-1-[(2~{S})-2-morpholin-4-ylpropyl]imidazol-2-yl]pyrrolidin-2-one × 1 DMS DIMETHYL SULFOXIDE × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Sodium citrate tribasic dihydrate, 20% w/v Polyethylene glycol 3,350	分辨率 1.42 Å R-free 0.227

共 135 个其他 PDB 条目、223 个 assembly。打开独立比较页并筛选聚集状态

查看构建体与数据证据

UniProt名称	CBP_HUMAN
Isoform	—
PDB实体	1
链与序列区间	作者链 A； PDB构建体 33–148； UniProt 1082–1197 作者链 B； PDB构建体 33–148； UniProt 1082–1197

页面优先展示蛋白身份、当前 assembly、共同组分、聚集状态和跨 PDB 结构链接。链映射与序列区间收在“数据证据”中；数据库内部编号、导入时间和 assembly 操作表达式仅用于维护，因此不在读者页面展示。

SAXS 散射曲线 SAXS Profile

P(r) 距离分布 P(r) Distribution

下载 Download SAXS (.dat) P(r) (.pr.out) CIF

▼

2. 结构基本信息 2. Structure Basics

条目编号 entry_id	5w0l
沉积日期 deposition_date	2017-05-31
结构标题 title	CREBBP Bromodomain in complex with Cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)
关键词 keywords	CREBBP, Bromodomain, small molecule inhibitor, TRANSCRIPTION REGULATOR-INHIBITOR complex; TRANSCRIPTION REGULATOR/INHIBITOR
实验方法 method	X-RAY DIFFRACTION

▼

3. SAXS 参数 (CRYSOL 理论计算) 3. SAXS Parameters (CRYSOL)

回转半径 Rg (Guinier) rg_guinier	24.28 Å
回转半径 Rg (电子) rg_electron	24.13 Å
零角强度 I(0) i0	12676400.00
分子量 molecular_weight	28036.0 kDa
排除体积 excluded_volume	35495 Å³
包络体积 envelope_volume	43477 Å³
水化壳体积 shell_volume	16553 Å³
包络直径 envelope_diameter	86.4 Å
壳层 Rg shell_rg	28.57 Å
包络 Rg envelope_rg	24.14 Å
形状 Rg shape_rg	24.14 Å
总 Rg total_rg	24.71 Å
总原子数 total_atoms	1982
残基数 n_residues	228
球谐函数阶数 n_harmonics	20
q 范围 q_range	— – 0.5000 Å⁻¹
数据点数 n_points	101
壳层类型 shell_type	directional
溶剂电子密度 solvent_density	0.3340 e/Å³
壳层衬度 contrast_shell	0.0300 e/Å³
CRYSOL 版本 crysol_version	4.1.3

▼

4. P(r) 距离分布 (GNOM 反演) 4. P(r) Analysis (GNOM)

最大尺寸 Dmax dmax	85.6 Å
Rg (实空间) rg_real	24.58 Å
Rg 误差 (实空间) rg_real_error	0.85 Å
I(0) (实空间) i0_real	1.2680e+07
I(0) 误差 (实空间) i0_real_error	1.9840e+05
Rg (倒空间) rg_reciprocal	24.51 Å
I(0) (倒空间) i0_reciprocal	12680000.0000
解质量估计 total_estimate	0.7801
解质量评级 solution_quality	GOOD a GOOD solution
P(r) 峰数 n_peaks	2
主峰位置 r_peak_primary	19.0 Å
偏度 Skewness skewness	0.525
峰度 Kurtosis kurtosis	-0.389
角度范围 angular_range	— – 0.3250 Å⁻¹
当前正则化参数 α current_alpha	0.0000
最高正则化参数 α highest_alpha	4967000.0000
实空间数据点数 n_real_points	64
GNOM 版本 gnom_version	4.1.3
质量判据 quality_criteria	AN1: 0.000; Oscil: 0.636; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.380; Smooth: 0.848

▶

5. 晶体学与实验 5. Crystallography & Experiment

▶

6. 实体与聚合物信息 Entities & Polymers (3)

实体 1 Entity 1 polymer

描述 description	CREB-binding protein
分子量 formula_weight	17630.0 kDa
EC 编号 ec_number	2.3.1.48
来源方法 src_method	man
拷贝数 entity_count	2

聚合物 Polymer

聚合物类型 type	polypeptide(L)
链编号 strand_id	A,B
原子数 atom_count	2225

MHHHHHHGSLVPRGSMDYKDDDDKENLYFQGSKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG

来源 Source

来源生物 organism	Homo sapiens
通用名 common_name	Human
NCBI 分类编号 ncbi_taxonomy_id	9606
宿主生物 host_organism	Escherichia coli

实体 2 Entity 2 non-polymer

描述 description	;1-{3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one ;
分子量 formula_weight	510.6 kDa
来源方法 src_method	syn
拷贝数 entity_count	2

实体 3 Entity 3 water

描述 description	water
分子量 formula_weight	18.0 kDa
来源方法 src_method	nat
拷贝数 entity_count	243

▼

7. 折叠分类 (SCOP + CATH) 4 domains

SCOP 2.08 (2 domains)

结构域编号 domain_id	d5w0la_
类 Class class	a — All alpha proteins
折叠类型 Fold fold	a.29 — Bromodomain-like
超家族 Superfamily superfamily	a.29.2 — Bromodomain
家族 Family family	a.29.2.1 — Bromodomain

结构域编号 domain_id	d5w0lb_
类 Class class	a — All alpha proteins
折叠类型 Fold fold	a.29 — Bromodomain-like
超家族 Superfamily superfamily	a.29.2 — Bromodomain
家族 Family family	a.29.2.1 — Bromodomain

CATH v4.4 (2 domains)

结构域编号 domain_id	5w0lA00
类 Class class	1 — Mainly Alpha
架构 Architecture architecture	20 — Up-down Bundle
拓扑 Topology topology	920 — Histone Acetyltransferase; Chain A
同源超家族 H-superfamily homologous superfamily	10 — Bromodomain-like

结构域编号 domain_id	5w0lB00
类 Class class	1 — Mainly Alpha
架构 Architecture architecture	20 — Up-down Bundle
拓扑 Topology topology	920 — Histone Acetyltransferase; Chain A
同源超家族 H-superfamily homologous superfamily	10 — Bromodomain-like

▶

8. 引用文献 (1)

▶

晶胞边长 a length_a	49.648 Å
晶胞边长 b length_b	34.055 Å
晶胞边长 c length_c	80.887 Å
晶胞夹角 α angle_alpha	90.00 °
晶胞夹角 β angle_beta	90.01 °
晶胞夹角 γ angle_gamma	90.00 °
晶胞分子数 Z z_pdb	4

空间群 space_group	P 1 21 1
空间群编号 int_tables_number	4
晶系 crystal_system	—

分辨率 resolution	1.549 Å
最低分辨率 resolution_low	28.083 Å
R 因子 r_factor	0.1944
R_work r_work	0.1925
R_free r_free	0.2294

fit	/app/data/saxs_computation/w0/5w0l/5w0l.fit
pddf	/app/data/pr_computation/w0/5w0l/5w0l.pr.out
profile	/app/data/saxs_computation/w0/5w0l/5w0l.dat